Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


USANA Q4 results

This article was originally published in The Tan Sheet

Executive Summary

USANA Health Sciences announces Jan. 10 it expects net sales for its fourth quarter ended Dec. 30, 2006 to be approximately $101 mil. before it reclassifies its financial report. The Salt Lake City-based firm says it will make an "immaterial reclassification to its consolidated financial statements beginning with the fourth quarter of 2006." USANA says the reclassification will reduce net sales by approximately 1.5%. The firm also says it anticipates net sales for full-year 2006 to be approximately $374 mil. The company also says it commenced operations in Malaysia on Jan. 8...

You may also be interested in...

USANA files lawsuit

USANA Health Sciences announces March 15 it has filed a lawsuit against the Fraud Discovery Institute and Barry Minkow in the U.S. District Court in Salt Lake City, Utah for defamation. In a March 15, 2007 Wall Street Journal article Minkow said he bought "put" options on USANA's shares in a bet the price will fall. The Salt Lake City-based firm says in a release it believes "this is a campaign to manipulate USANA's stock price that is being orchestrated by an individual who served 7 years in prison for stock fraud." The company says Minkow's assertions about USANA's sales model are "false and misleading." In January the firm said it expected net sales for its fourth quarter to be approximately $101 mil. before it reclassified its financial report (1"The Tan Sheet," Jan. 15, 2007, In Brief)...

More Top-Level Pharma Changes In India, Cipla Gets CSO

Top-level personnel movement continues at pharma firms in India, with Cipla now appointing an ex-Amneal executive as its Chief Scientific Officer, while Abbott has effected a rejig at the helm.

India Acts To Limit Supply Disruption From Coronavirus

Indian pharmaceutical companies will soon be asked to seek a no objection certificate for the export of 12 APIs and their formulations, as the country deals with Chinese raw material supply disruptions on the back of the coronavirus crisis. However, the move is not expected to impact the export quantum for now.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts